|
Articles
Hits
Linfa
News
Projects
Reports
Links
Sitemap
Underbreath
|
|
Updating
of published results
The articles listed
and (whenever possible) linked in this
section do not necessarily need
to originate within the Callerio Foundation:
all relevant contributions by our visitors
will be considered with due attention.
|
|
Claudine Scolaro, Adrian B. Chaplin, Christian
G. Hartinger, Alberta Bergamo, Moreno Cocchietto,
Bernhard K. Keppler, Gianni Sava and Paul
J. Dyson
Tuning the hydrophobicity
of ruthenium(II)–arene (RAPTA) drugs
to modify uptake, biomolecular interactions
and efficacy
Dalton Trans. ;5065 - 5072;
2007.
The 5th of the top ten most popular Dalton
Transactions articles accessed online during
September
2007 PDF |
Vock CA, Ang WH, Scolaro C, Phillips AD,
Lagopoulos L, Juillerat-Jeanneret L, Sava
G, Scopelliti R, Dyson PJ.
Development
of ruthenium antitumor drugs that overcome
multidrug resistance mechanisms
J Med Chem. ;50(9):2166-75;
3 May 2007; Epub 10 Apr 2007. |
Bergamo A,
Sava G.
Ruthenium
complexes can target determinants of tumour
malignancy
Dalton Trans. ;(13):1267-72;
7 Apr 2007; Epub 28 Feb 2007.
The most popular Dalton Transactions article
during March
2007(778
hits) and in the top ten during
April
2007.
|
Vock CA, Scolaro
C, Phillips AD, Scopelliti R, Sava G, Dyson
PJ.
Synthesis,
characterization, and in vitro evaluation
of novel ruthenium(II) eta6-arene imidazole
complexes
J Med Chem. ; 49(18):5552-61;
7 Sep 2006. |
Khalaila I,
Bergamo A, Bussy F, Sava G, Dyson PJ.
The
role of cisplatin and NAMI-A plasma-protein
interactions in relation to combination
therapy
Int J Oncol. ; 29(1):261-8.;Jul
2006. |
Dyson PJ, Sava
G.
Metal-based
antitumour drugs in the post genomic era
Dalton Trans;(16):1929-33.;
28 Apr 2006; Epub 28 Mar 2006. |
Coradini D,
Pellizzaro C, Scarlata I, Zorzet S, Garrovo
C, Abolafio G, Speranza A, Fedeli M, Cantoni
S, Sava G, Daidone MG, Perbellini A.
A
novel retinoic/butyric hyaluronan ester
for the treatment of acute promyelocytic
leukemia: preliminary preclinical results
Leukemia ;20(5):785-92;May
2006 . |
Gava B, Zorzet
S, Spessotto P, Cocchietto M, Sava G.
Inhibition
of B16 Melanoma Metastases with the Ruthenium
Complex Imidazolium trans-Imidazoledimethylsulfoxide-tetrachlororuthenate
and Down-regulation of Tumor Cell Invasion
J. Pharmacol. Exp. Ther.;
317(1): 284-91, Apr 2006. |
Paolini A,
Ridolfi V, Zezza D, Cocchietto M, Musa M,
Pavone A, Conte A, Giorgetti G.
Vaccination
trial of sea-bass (Dicentrarchus labrax)
against pasteurellosis using oral, intraperitoneal
and bath administration
Veterinaria Italiana; 41(2),
7-14, Apr-Jun 2005. |
Zorzin L, Cocchietto
M, Voinovich D, Marcuzzi A, Filipovic Grcic,
Mulloni C, Crembiale G, Casarsa C, Bulla
R, Sava G.
Lysozyme-containing
chitosan-coated alginate microspheres for
oral immunisation
J. Drug Del. Sci. Tech; 16(6),
413-420, 2005 |
Scolaro C,
Geldbach TJ, Rochat S, Dorcier A, Gossens
C, Bergamo A, Cocchietto M, Tavernelli I,
Sava G, Rothlisberger U, Dyson PJ.
Influence
of Hydrogen-Bonding Substituents on the
Cytotoxicity of RAPTA Compounds
Organometallics; 25:756-65
First
in
Most-Cited Articles in
the last two month (Hot Papers - September
2007)PDF
Third
of the Organometallic
Most-Cited Articles in
2006
|
Scolaro C,
Bergamo A, Brescacin L, Delfino R, Cocchietto
M, Laurenczy G, Geldbach TJ, Sava G, Dyson
PJ.
In
vitro and in vivo evaluation of ruthenium(II)-arene
PTA complexes.
J. Med. Chem.; 48(12):4161-71,
Jun 16 2005.
Second of the Journal of Medicinal
chemistry
Most-Cited Articles in
the last two month (Hot Papers - September
2007)PDF
|
Papadia P,
Margiotta N, Bergamo A, Sava G, Natile G.
Platinum(II)
complexes with antitumoral/antiviral aromatic
heterocycles: effect of glutathione upon
in vitro cell growth inhibition.
J. Med. Chem.; 48(9):3364-71,
May 5 2005. |
Frausin F,
Scarcia V, Cocchietto M, Furlani A, Serli
B, Alessio E, Sava G.
Free
exchange across cells, and echistatin-sensitive
membrane target for the metastasis inhibitor
NAMI-A (imidazolium trans-imidazole dimethyl
sulfoxide tetrachlororuthenate) on KB tumor
cells.
J. Pharmacol. Exp. Ther.;
313(1):227-33, Apr 2005. Epub 2004 Dec 3. |
Alessio E,
Mestroni G, Bergamo A, sava G.
Ruthenium
antimetastatic agents.
Curr Top Med Chem.;4(15):1525-35,
2004 |
Casarsa
C, Mischis MT, Sava G.
TGFß1
regulation and collagen-release-independent
connective tissue re-modelling by the ruthenium
complex NAMI-A in solid tumours.
J Inorg Biochem.;98(10):1648-54, |
Margiotta
N, Bergamo A, Sava G, Padovano G, de Clercq
E, Natile G.
Antiviral
properties and cytotoxic activity of platinum(II)
complexes with 1,10-phenanthrolines and
acyclovir or penciclovir.
J Inorg Biochem.;98(8):1385-90, |
Coradini
D, Zorzet S, Rossin R, Scarlata I, Pellizzaro
C, Turrin C, Bello M, Cantoni S, Speranza
A, Sava G, Mazzi U, Perbellini A.
Inhibition
of hepatocellular carcinomas in vitro and
hepatic metastases in vivo in mice by the
histone deacetylase inhibitor HA-But.
Clin Cancer Res.;10(14):4822-30,
|
Bacac
M, Vadori M, Sava G, Pacor S.
Cocultures
of metastatic and host immune cells: selective
effects of NAMI-A for tumor cells.
Cancer Immunol Immunother.;
Jun 25 |
Alessio
E, Mestroni G, Bergamo A, Sava G.
Ruthenium
anticancer drugs.
Met Ions Biol Syst.;42:323-51,
2004 |
Sava
G, Frausin F, Cocchietto M, Vita F, Podda
E, Spessotto P, Furlani A, Scarcia V, Zabucchi
G.
Actin-dependent
tumour cell adhesion after short-term exposure
to the antimetastasis ruthenium complex
NAMI-A.
Eur J Cancer.; 40(9):1383-96,
|
Ravera
M, Baracco S, Cassino C, Colangelo D, Bagni
G, Sava G, Osella D.
Electrochemical
measurements confirm the preferential bonding
of the antimetastatic complex [ImH][RuCl(4)(DMSO)(Im)]
(NAMI-A) with proteins and the weak interaction
with nucleobases.
J Inorg Biochem.; 98(6):984-90, |
Coradini
D, Pellizzaro C, Abolafio G, Bosco M, Scarlata
I, Cantoni S, Stucchi L, Zorzet S, Turrin
C, Sava G, Perbellini A, Daidone MG.
Hyaluronic-acid
butyric esters as promising antineoplastic
agents in human lung carcinoma: a preclinical
study.
Invest New Drugs.; 22(3):207-17 |
Pacor
S, Zorzet S, Cocchietto M, Bacac M, Vadori
M, Turrin C, Gava B, Castellarin A, Sava
G.
Intratumoral
NAMI-A Treatment Triggers Metastasis Reduction,
Which Correlates to CD44 Regulation and
Tumor Infiltrating Lymphocyte Recruitment.
J Pharmacol Exp Ther.; 310(2):737-44, |
Hotze
AC, Caspers SE, de Vos D, Kooijman H, Spek
AL, Flamigni A, Bacac M, Sava G, Haasnoot
JG, Reedijk J.
Structure-dependent
in vitro cytotoxicity of the isomeric complexes
[Ru(L)(2)Cl(2)] (L= o-tolylazopyridine and
4-methyl-2-phenylazopyridine) in comparison
to [Ru(azpy)(2)Cl(2)].
J Biol Inorg Chem.; 9(3):354-64,
Apr 2004 |
Velders
AH, Bergamo A, Alessio E, Zangrando E, Haasnoot
JG, Casarsa C, Cocchietto M, Zorzet S, Sava
G.
Synthesis
and chemical-pharmacological characterization
of the antimetastatic NAMI-A-type Ru(III)
complexes (Hdmtp)[trans-RuCl4(dmso-S)(dmtp)],
(Na)[trans-RuCl4(dmso-S)(dmtp)], and [mer-RuCl3(H2O)(dmso-S)(dmtp)]
(dmtp = 5,7-dimethyl[1,2,4]triazolo[1,5-a]pyrimidine).
J Med Chem. 47(5):1110-21,
Feb 2004 |
Bacac
M, Hotze AC, Schilden K, Haasnoot JG, Pacor
S, Alessio E, Sava G, Reedijk J.
The
hydrolysis of the anti-cancer ruthenium
complex NAMI-A affects its DNA binding and
antimetastatic activity: an NMR evaluation.
J Inorg Biochem.;98(2):402-12,Feb
2004
|
Turel
I, Pecanac M, Golobic A, Alessio E, Serli
B, Bergamo A, Sava G.
Solution,
solid state and biological characterization
of ruthenium(III)-DMSO complexes with purine
base derivatives.
J Inorg Biochem.;98(2):393-401,
Feb 2004
|
Ferrari
MB, Bisceglie F, Pelosi G, Tarasconi P,
Albertini R, Dall'Aglio PP, Pinelli S, Bergamo
A, Sava G.
Synthesis,
characterization and biological activity
of copper complexes with pyridoxal thiosemicarbazone
derivatives. X-ray crystal structure of
three dimeric complexes.
J Inorg Biochem.;98(2):301-312,
Feb 2004
|
Bergamo
A, Stocco G, Casarsa C, Cocchietto M, Alessio
E, Serli B, Zorzet S, Sava G.
Reduction
of in vivo lung metastases by dinuclear
ruthenium complexes is coupled to inhibition
of in vitro tumour invasion.
Int J Oncol.;24(2):373-9,
Feb 2004
|
Bergamo
A, Messori L, Piccioli F, Cocchietto M,
Sava G.
Biological
role of adduct formation of the ruthenium(III)
complex NAMI-A
with serum albumin and serum transferrin.
Invest New Drugs.;21(4):401-115,
Nov 2003
|
Debidda
M, Sanna B, Cossu A, Posadino AM, Tadolini
B, Ventura C, Pintus G.
NAMI-A
inhibits the PMA-induced ODC gene expression
in ECV304 cells: involvement of PKC/Raf/Mek/ERK
signalling pathway.
Int J Oncol.;23(2):477-82,
Aug 2003
|
Sava
G, Zorzet S, Turrin C, Vita F, Soranzo M,
Zabucchi G, Cocchietto M, Bergamo A, DiGiovine
S, Pezzoni G, Sartor L, Garbisa S.
Dual
Action of NAMI-A in Inhibition of Solid
Tumor Metastasis: Selective Targeting of
Metastatic Cells and Binding to Collagen
Clin Cancer Res; 9(5):1898-1905,
May 2003
|
|
Cocchietto M, Zorzet S,
Sorc A, Sava G
Primary
tumor, lung and kidney retention and antimetastasis
effect of NAMI-A following different routes
of administration
Investigational New
Drugs; 21: 55-62, 2003 |
Bergamo
A, Stocco G, Gava B, Cocchietto M, Alessio
E, Serli B, Iengo E, Sava G.
Distinct
effects of dinuclear ruthenium(III) complexes
on cell proliferation and on cell cycle
regulation in human and murine tumor cell
lines
J Pharmacol Exp Ther;
305(2):725-32, May 2003
CONTINUE >
|
|
|
|
